GE in blood plasma fractionation tieup.
The alliance will combine GE Healthcare's expertise in bioprocessing for plasma fractionation with Neste Jacobs's global bio-engineering and construction capabilities.
Together, the companies will offer governments and pharmaceutical companies an integrated, cost-competitive "turn-key" solution for the construction of plasma fractionation plants, to help meet the rising worldwide demand for these potentially life-saving treatments.
The alliance between the two companies aligns with GE's healthymagination initiative, which focuses on reducing cost, increasing access and improving quality in healthcare.
Olivier Loeillot, general manager of Enterprise Solutions, GE Healthcare Life Sciences said, "One of the key healthcare challenges in the Middle East region is the growing incidence of blood related disorders, several of them genetic in nature."
"While several governmental agencies and involved in promoting awareness of these disease conditions, by further enabling the healthcare sector with the advanced technologies, we can accelerate diagnosis and thus potentially improve treatment possibilities."
"The new venture could bring play a transformational role in reshaping the bloom plasma treatment and solutions in the region," he noted.
Human blood plasma, the liquid component of blood, is the source of many proteins such as Factor VIII, Factor IX, Immunoglobulin and Albumin.
These protein products, which are purified from plasma by a process known as fractionation, are used to treat a wide variety of serious and often life-threatening conditions such as shock, trauma, infections, immunological disorders, Hemophilia A and B, and other blood disorders.
The global demand for blood plasma products is predicted to grow from $13 billion in 2009 to an estimated $26.5 billion by 2015.
However healthcare providers in many countries, especially emerging nations, are unable to meet demand for these treatments.
The World Federation of Hemophilia estimates that globally 400,000 people are living with hemophilia, of whom only 25 per cent receive adequate treatment.
Helping countries to become self-sufficient in the fractionation of locally collected plasma will overcome many of these unmet healthcare needs.
Jarmo Suominen, the managing director and CEO said "Neste Jacobs has over 30 years' experience in the design of plasma fractionation plants, all over the world, and we're delighted to form this alliance with GE Healthcare."
"We have a shared vision of bringing an integrated approach to plasma fractionation, to drive efficiency and simplicity in the construction of new plants."
"Combining the unique competences and know-how of our respective companies will help secure the delivery of turn-key solutions to the plasma products industry including construction of complete green field facilities."
"This alliance gives us an excellent opportunity to better serve clients investing in plasma fractionation world-wide, he added.- TradeArabia News Service
Copyright 2011 www.tradearabia.com
Copyright 2011 Al Hilal Publishing & Marketing Group
Provided by Syndigate.info an Albawaba.com company